Synopsis

Source of validity: Scientific
Rating (out of 5): 3

L-alanyl-L-glutamine, a stable dipeptide form of glutamine, has been investigated for its potential to reduce certain side effects of chemotherapy, particularly gastrointestinal toxicity (such as mucositis and diarrhea) and peripheral neuropathy. Glutamine is a conditionally essential amino acid that supports gut mucosal integrity and immune function, both of which can be compromised during chemotherapy. Studies suggest that oral or intravenous supplementation with L-alanyl-L-glutamine may help maintain the integrity of the intestinal mucosa, reduce inflammation, and promote faster recovery of damaged tissues. A number of randomized controlled trials and meta-analyses have reported a reduction in the severity and incidence of oral mucositis and diarrhea in patients receiving chemotherapy (especially with drugs like 5-fluorouracil and irinotecan) who also received glutamine or L-alanyl-L-glutamine supplementation. However, the strength of evidence varies by cancer type, chemotherapy regimen, and study design, leading to some inconsistency in clinical guidelines. While some oncology societies cautiously support its use in specific settings, others call for more high-quality research before recommending routine supplementation. Overall, there is moderate scientific validation for the use of L-alanyl-L-glutamine in reducing certain chemotherapy side effects, although it is not universally accepted as standard of care.

More about L-alanyl-L-glutamine
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by L-alanyl-L-glutamine

Products containing L-alanyl-L-glutamine